Seite auswählen

Characterizing Sex Differences in the Tau[P301S] Mouse Model of Tauopathies.

18. März 2026

Sex differences in preclinical tauopathy models remain undercharacterized, yet they carry important implications for study design and translational validity. Presented at AD/PD 2026 in Copenhagen, this poster describes a longitudinal phenotyping study of male and female Tau[P301S] mice from 2 to 5.25 months of age. 

Our data reveal meaningful sex-specific differences: female Tau[P301S] mice display pronounced hyperactivity in automated home-cages and significant cognitive deficits at 4 months — including impaired spatial memory in the Morris Water Maze and selective discrimination learning deficits in the CognitionWall™ — while motor coordination impairments on the balance beam are comparable between sexes. These findings support inclusion of both sexes in preclinical cohorts when evaluating therapeutic candidates targeting tau pathology in Alzheimer’s disease and frontotemporal dementia (FTD). 

Conference  AD/PD™ 2026 — 20th International Conference on Alzheimer’s and Parkinson’s Diseases 
Dates  March 17–21, 2026 
Location  Bella Center Copenhagen, Copenhagen, Denmark 
Booth  #25 
Authors  Sofie Carmans, Thomas Vogels, Ha Pham, Maarten Loos 
Affiliation  InnoSer neurology group, Diepenbeek, Belgium; InnoSer neurology group, Leiden, Netherlands 
Geschlechtsspezifische Unterschiede in präklinischen Tauopathie-Modellen sind bislang noch unzureichend charakterisiert, haben jedoch wichtige Auswirkungen auf die Studienkonzeption und die translationale Validität. Dieses Poster, das auf der AD/PD 2026 in Kopenhagen vorgestellt wurde, beschreibt eine longitudinale Phänotypisierungsstudie an männlichen und weiblichen Tau[P301S]-Mäusen im Alter von 2 bis 5,25 Monaten.

Zusammenfassung

The homozygous Tau[P301S] (Thy1-TauP301S) mouse is one of the most widely used preclinical models for evaluating therapeutics targeting tauopathies. This model overexpresses human tau carrying the disease-associated P301S mutation, with tau pathology emerging from approximately 3 months and associated behavioral phenotypes developing around 4 months of age. 

Although previous studies suggest that male and female Tau[P301S] mice exhibit a similar onset of tau pathology, their phenotypic differences remain largely undercharacterized. In this study, we systematically evaluated both male and female Tau[P301S] mice from 2 to 5.25 months of age to capture potential sex-specific differences and improve the translational relevance of preclinical study design. 

Motor function was assessed using spontaneous behavior monitoring in automated PhenoTyper home-cages, rotarod, balance beam, grip strength, open field, and CatWalk gait analysis. Cognitive testing at 4 months included novel object recognition (NOR), PhenoTyper CognitionWall™, and Morris Water Maze. Blood was collected longitudinally for plasma neurofilament light chain (NfL) analysis, and organs collected for histopathology at termination. 

Female Tau[P301S] mice displayed stronger hyperactivity than males at younger ages. Both sexes developed comparable motor coordination impairments on the balance beam. Only female Tau[P301S] mice exhibited cognitive deficits at 4 months, including impaired spatial memory in the Morris Water Maze probe trial and selective discrimination learning deficits in the CognitionWall™. No significant sex differences were observed in the NOR test. 

These findings highlight the importance of including both sexes in preclinical tauopathy studies and support more representative cohort design for Alzheimer’s disease and frontotemporal dementia therapeutic evaluation. 

Bleiben Sie neugierig: Weitere Forschungsansätze

Cognitive profiling in the APP[V717I]xTau[P301S] mouse model

Cognitive profiling in the APP[V717I]xTau[P301S] mouse model

In this month's update, we revisit the APP[V717I]xTau[P301S] model with newly in-house generated Morris Water Maze (MWM) data, reconfirming the spatial memory deficits previously described for this model and reinforcing the translational value of the model.The...

Aktuelle Artikel

Alle Kategorien

Seien Sie als Erster informiert – erhalten Sie diese Neuigkeiten direkt in Ihren Posteingang

InnoSer bietet eine Vielzahl validierter In-vitro- und In-vivo-Plattformen für die effiziente Entwicklung neuartiger Therapeutika. Wenn Sie weitere Informationen benötigen, können Sie sich gerne an uns wenden – wir melden uns innerhalb weniger Tage bei Ihnen.

Wir veröffentlichen monatlich einen Newsletter aus unseren InnoSer-Labors mit wissenschaftlichen Einblicken in unsere Forschungsdienstleistungen. Um die Neuigkeiten direkt in Ihren Posteingang zu erhalten, melden Sie sich bitte hier an.